Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 2, 2018, Pages

  Grabosch, Shannon M ^a   Shariff, Osman M ^b   Helm, C William ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b University of Louisville School of Medicine   (United States)

^c ROYAL CORNWALL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; ROFECOXIB; SULINDAC; VALDECOXIB; LACTONE; SULFONAMIDE; SULFONE;

CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER REGRESSION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TUMOR INVASION; UTERINE CERVIX CARCINOMA IN SITU; ADULT; DISEASE EXACERBATION; FEMALE; INDUCTION CHEMOTHERAPY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROCEDURES; UTERINE CERVIX TUMOR;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELECOXIB; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LACTONES; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; SULFONES; UTERINE CERVICAL NEOPLASMS;

EID: 85041954791     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004121.pub4     Document Type: Review

References (70)

1. Farley JH, Truong V, Goo E, Uyehara C, Belnap C, Larsen WI. A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical neoplasia. Gynecologic Oncology 2006;103(2):425-30. [PUBMED: 16677697]2607828
2. Hefler LA, Grimm C, Speiser P, Sliutz G, Reinthaller A. The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III. A phase II trial. European Journal of Obstetrics and Gynecology and Reproductive Biology 2005;125(2):251-4. [PUBMED: 16188370]2607830
3. Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, et al. A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology 2017;145(2):291-7. 7504168
4. Ferrandina G, Ranelletti FO, Legge F, Lauriola L, Salutari V, Gessi M, et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clinical Cancer Research 2003;9(12):4324-31. [PUBMED: 14555502]2607832
5. Herrera FG, Chan P, Doll C, Milosevic M, Oza A, Syed A, et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. International Journal of Radiation Oncology, Biology and Physics 2006;67(1):97-103. [PUBMED: 17056201]2607834
6. Mitchell MF, Hittelman WK, Lotan R, Nishioka K, Tortolero-Luna G, Richards-Kortum R, et al. Chemoprevention trials and surrogate end point biomarkers in the cervix. Cancer 1995;76(10 Suppl):1956-77. [PUBMED: 8634987]2607836
7. Vlastos AT, Schottenfeld D, Follen M. Biomarkers and their use in cervical cancer chemoprevention. Critical Reviews in Oncology Hematology 2003;46(3):261-73. [PUBMED: 12791426]2607838
8. Alvarez RD, Conner MG, Weiss H, Klug PM, Niwas S, Manne U, et al. The efficacy of 9-cis retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double blind clinical trial. Cancer, Epidemiology, Biomarkers & Prevention 2003;12(2):114-9. [PUBMED: 12582020]
9. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, et al. PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. New England Journal of Medicine 2006;355:885-95. [PUBMED: 16943401]
10. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284. [PUBMED: 18801868]
11. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. New England Journal of Medicine 2006;355(9):873-84. [PUBMED: 16943400]
12. Bleecker E, Koehler E, Smith J, Budwit D, Rahangdale L. Outcomes after management of young women with cervical intraepithelial neoplasia 2 with a 6-month observation protocol. Journal of Lower Genital Tract Disease 2014;18(1):46-9. [PUBMED: 23959297]
13. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. Journal of Cell Physiology 2002;190(3):279-86. [PUBMED: 11857443]
14. DeWitt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochimica et Biophysica Acta 1991;1083(2):121-34. [PUBMED: 1903657]
15. Dursun P, Yuce K, Usubutun A, Ayhan A. Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopathologic variables. International Journal of Gynecological Cancer 2007;17(1):164-73. [MEDLINE: 17291249]
16. Eberhart CE, Coffey RJ, Radhik A. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107(4):1183-8. [PUBMED: 7926468]
17. Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. Journal of the National Cancer Institute 2010;102(24):1835-44. [PUBMED: 21115882]
18. Farley J, Uyehara C, Hashiro G, Belnap C, Birrer M, Salminen E. Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure. Gynecologic Oncology 2004;92(2):596-602. [MEDLINE: 14766253]
19. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010;127(12):2893-917. [PubMed:: 21351269]
20. Ferrandina G, Lauriola L, Zannoni GF, Distefano MG, Legge F, Salutari V, et al. Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. Cancer 2002;87(10):1145-52. [MEDLINE: 12402155]
21. Ferrandina G, Lauriola L, Distefano MF, Zannoni GF, Gessi M, Legge F, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. Journal of Clinical Oncology 2002;20(4):973-81. [MEDLINE: 11844819]
22. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubert RA, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet-light induced skin carcinogenesis. Molecular Carcinogenesis 1999;25(4):231-40. [PUBMED: 10449029]
23. Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer prevention. Cancer Prevention Research 2011;4(11):1728-35. [PUBMED: 21778329]
24. Follen M, Atkinson EN, Schottenfeld D, Malpica A, West L, Lippman S, et al. A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clinical Cancer Research 2001;7(11):3356-65. [PUBMED: 11705848]
25. Gaffney DK, Holden J, Davies M. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. International Journal of Radiation, Oncology, Biology and Physics 2001;49(5):1213-7. [PUBMED: 11286825]
26. Gaffney DK, Haslam D, Tsodikov A, Hammond E, Seaman J, Holden J, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. International Journal of Radiation Oncology Biology Physics 2003;56(4):922-8. [PUBMED: 12829126]
27. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. Journal of Clinical Investigation 2006;116(1):4-15. [PUBMED: 16395396]
28. Harris RE, Alshafie GA, Abou-Isaa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Research 2000;60(8):2101-3. [PUBMED: 10786667]
29. Herschman HR. Prostaglandin synthase 2. Biochimica et Biophysica Acta 1996;1299(1):125-40. [PUBMED: 8555245]
30. Hia T, Neilson K. Human cyclooxygenase-2 cDNA. Proceedings of National Academy of Science USA 1992;89(16):7384-8. [PUBMED: 1380156]
31. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
32. Huang D, Skollard D, Sharma S. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up regulation of interleukins 10 and down regulation of interleukins 12 production. Cancer Research 1998;58(6):1208-16. [MEDLINE: 9515807]
33. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. Journal of the National Cancer Institute 1998;90(6):455-60. [MEDLINE: 9521170]
34. Jaisamrarn U, Castellsagué X, Garland SM, Naud P, Palmroth J, Del Rosario-Raymundo MR, et al. HPV PATRICIA Study Group. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLOS One 2013;8(11):e79260. [PUBMED: 24260180]
35. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor against colon carcinogenesis. Cancer Research 1998;58(3):409-12. [PUBMED: 9458081]
36. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Doody LA. New agents for cancer chemoprevention. Journal of Cellular Biochemistry 1996;26S:1-28. [MEDLINE: 97298750]
37. Kim YB, Kim GE, Cho NH, Pyo HR, Shim SJ, Chang SK, et al. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 2002;95(3):531-9. [MEDLINE: 12209745]
38. Kim MH, Seo SS, Song YS, Kang DH, Park IA, Kang SB, et al. Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes. Gynecologic Oncology 2003;90(1):83-90. [PUBMED: PMID: 12821346]
39. Kim JY, Lim SJ, Park K, Lee CM, Kim J. Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecologic Oncology 2005;97(2):337-41. [MEDLINE: 15863127]
40. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clinical Cancer Research 2001;7:429-34. [MEDLINE: 11234900]
41. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clinical Cancer Research 2000;6(2):519-25. [MEDLINE: 10690533]
42. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. Journal of Urology 2000;164(3):820-5. [PUBMED: 10953162]
43. Martin-Hirsch PPL, Paraskevaidis E, Bryant A, Dickinson HO, Keep SL. Surgery for cervical intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD001318.pub3; PUBMED: 20556751]
44. Mitchell A, Newton JM, Brite K, Einspahr J, Ellis M, Davis J, et al. Cyclooxygenase 2 expression in cervical intraepithelial neoplasia and vulvar cancer. Journal of Lower Genital Tract Disease 2007;11(2):80-5. [MEDLINE: 17415111]
45. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Research 1999;59(22):5647-50. [MEDLINE: 10582676]
46. Munkarah A, Ali-Fehmi R. COX-2: a protein with an active role in gynecological cancers. Current Opinion in Obstetrics and Gynecology 2005;17(1):49-53. [PUBMED: 15711411]
47. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(Suppl 3):S1-S10. [PUBMED: 16949995]
48. Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Research 1981;41(5):1954-7. [PUBMED: 7214363]
49. Okajima E, Denda A, Ozono S, Takahama M, Akai H, Sasaki Y, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Research 1998;58(14):3028-31. [PUBMED: 9679967]
50. Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treatment Reviews 2004;30:205-11. [PUBMED: 15023438]
51. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Annals of Surgical Oncology 2004;11(3):328-39. [MEDLINE: 14993030]
52. Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. New England Journal of Medicine 2006;355(9):950-2. [PUBMED: 16943408]
53. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Research 2000;60(2):293-7. [PUBMED: 10667579]
54. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
55. Ryu HS, Chang KH, Yang HW, Kim MS, Kwon HC, Oh KS. High cyclooxygenase-2 expression in stage 1B cervical cancer with lymph node metastasis or parametrial invasion. Gynecologic Oncology 2000;76(3):320-5. [MEDLINE: 10684704]
56. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the oesophagus. Clinical Cancer Research 2000;6(4):1229-38. [MEDLINE: 10778945]
57. Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. Journal of Urology 2003;169(3):938-42. [MEDLINE: 12576817]
58. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clinical Cancer Research 2000;6(6):2424-30. [MEDLINE: 10873095]
59. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. International Journal of Cell Biology 2010 Mar 17 [Epub ahead of print]. [PUBMED: 20339581]
60. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89(12):2637-45. [MEDLINE: 11135226]
61. Soutter WP, de Barros Lopes A, Fletcher A, Monaghan JM, Duncan ID, Paraskevaidis E, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997;349(9057):978-80. [PUBMED: 9100623]
62. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, et al. Specific inhibition of cyclooxygenase-2 restores tumor reactivity by altering the balance of IL-10 and IL-12 synthesis. Journal of Immunology 2000;164(1):361-70. [PUBMED: 10605031]
63. Surh Y-J, Kundu JM. Signal transduction network leading to COX-2 induction: a road map in search of cancer chemopreventives. Archives of Pharmacal Research 2005;28(1):1-15. [PUBMED: 15742801]
64. Tan KB, Putti TC. Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications. Journal of Clinical Pathology 2005;58(5):535-8. [MEDLINE: 15858127]
65. Tsujii M, Dubois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase 2. Cell 1995;83(3):493-501. [PUBMED: 8521479]
66. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of National Academy of Science USA 1997;94(7):3336-40. [PUBMED: 9096394]
67. Tsujii M, Kawano S, Tsujii S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93(5):705-16. [PUBMED: 9630216]
68. Grabosch SM, Shariff OM, Wulf JL, Helm CW. Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD004121.pub3]
69. Helm CW, Meyer NJ. Anti-inflammatory agents for preventing the progression of cervical intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD004121]
70. Shariff OM, Wulff JL, Helm CW. Anti-inflammatory agents for preventing the progression of cervical intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD004121.pub2]